Predictive Oncology, based in Pittsburgh, PA, is a pioneering company at the forefront of oncology drug discovery and development. Through their innovative AI-driven platform, PEDAL, which utilizes a biobank of over 150,000 tumor samples, Predictive Oncology is revolutionizing the field by predicting drug responses with 92% accuracy and increasing the probability of success in drug development.
With a focus on bringing the human element into oncology drug development earlier, Predictive Oncology's cutting-edge approach allows for the repurposing of failed drug compounds, improved portfolio diversity, and optimized drug-tumor pairing. Their groundbreaking work with disruptive technology is shaping the future of oncology research and paving the way for more confident predictions in drug response outcomes.
Generated from the website